Role of gut microbiota in the pathogenesis and therapeutics of minimal hepatic encephalopathy via the gut-liver-brain axis  

作　　者：Ming Luo Rui-Juan Xin Fang-Rui Hu Li Yao Sheng-Juan Hu Fei-Hu Bai 

机构地区：[1]Department of Gastroenterology,People’s Hospital of Ningxia Hui Autonomous Region,Yinchuan 750021,Ningxia Hui Autonomous Region,China

出　　处：《World Journal of Gastroenterology》2023年第1期144-156,共13页世界胃肠病学杂志（英文版）

基　　金：Ningxia Natural Science Foundation,No.2020AAC03329;the Key Research and Development Projects of Ningxia,No.2022BEG03128.

摘　　要：Minimal hepatic encephalopathy(MHE) is a frequent neurological and psychiatric complication of liver cirrhosis. The precise pathogenesis of MHE is complicated and has yet to be fully elucidated. Studies in cirrhotic patients and experimental animals with MHE have indicated that gut microbiota dysbiosis induces systemic inflammation, hyperammonemia, and endotoxemia, subsequently leading to neuroinflammation in the brain via the gut-liver-brain axis. Related mechanisms initiated by gut microbiota dysbiosis have significant roles in MHE pathogenesis. The currently available therapeutic strategies for MHE in clinical practice, including lactulose, rifaximin, probiotics, synbiotics, and fecal microbiota transplantation, exert their effects mainly by modulating gut microbiota dysbiosis. Microbiome therapies for MHE have shown promised efficacy and safety;however, several controversies and challenges regarding their clinical use deserve to be intensively discussed. We have summarized the latest research findings concerning the roles of gut microbiota dysbiosis in the pathogenesis of MHE via the gut-liver-brain axis as well as the potential mechanisms by which microbiome therapies regulate gut microbiota dysbiosis in MHE patients.

关 键 词：Gut microbiota Minimal hepatic encephalopathy Gut-liver-brain axis Pathogenesis THERAPEUTICS 

分 类 号：R575.3[医药卫生—消化系统]